However, the efficacy of the CD3-BAFFR-PD-L1 tribody may vary among different B-cell lymphoma subtypes due to differences in BAFFR and PD-L1 expression levels. This evidence concerns the gene TNFRSF13C and B-cell non-Hodgkin lymphoma.